CMR-Based Characterization of Cardiac Amyloidosis  by Barison, Andrea et al.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 7 , N O . 1 0 , 2 0 1 4 Letters to the Editor
O C T O B E R 2 0 1 4 : 1 0 6 2 – 8
1067CMR-Based Characterization of
Cardiac AmyloidosisAmyloidosis is a systemic disease caused by the
deposition of misfolded proteins. Cardiac involve-
ment is a major cause of morbidity and mortality,
especially in the light chain (AL) and transthyretin
(ATTR) forms. Amyloidosis usually presents as a
restrictive cardiomyopathy with progressive systolic/
diastolic dysfunction and arrhythmias but is often
misdiagnosed as hypertrophic or hypertensive heart
disease.
Recent evidence has supported the value of car-
diac magnetic resonance (CMR) as a noninvasive
diagnostic tool to detect cardiac amyloidosis, which
is characterized by marked myocardial interstitial
expansion leading to a typical early and diffuse
contrast enhancement. Dungu et al. (1) wrote an
interesting paper describing the differential CMR
characteristics according to the amyloid type (46 AL,
51 ATTR, 2 serum amyloid A, 1 apolipoprotein A-I).
Cardiac amyloidosis was conﬁrmed by endomyo-
cardial biopsy in 50 patients, whereas the other 50
patients had a positive extracardiac biopsy combined
with echocardiographic criteria for cardiac amyloid-
osis (2). Contrast enhancement was present in 99
patients, was more extensive in ATTR amyloidosis
than in AL amyloidosis, and was incorporated into a
scoring system (Query Amyloid Late Enhancement)
that independently differentiated ATTR amyloidosis
from AL amyloidosis. Despite poorer left ventricular
systolic function and worse biventricular hypertro-
phy, patients with ATTR amyloidosis experienced a
better outcome than did those with AL amyloidosis.
Nevertheless, the study did not examine all
possible parameters provided by a standard CMR
scan. Right ventricular volumes, mass, and ejection
fraction, which provide a more detailed character-
ization of right ventricular morphology and function
than right ventricular wall thickness alone, were not
measured. Moreover, the Query Amyloid Late
Enhancement score did not include contrast en-
hancement of the atrial chambers, which is a com-
mon ﬁnding in patients with cardiac amyloidosis
and in this study resulted in a difference between
patients with ATTR amyloidosis and patients with
AL amyloidosis. Finally, gadolinium kinetics in the
myocardium and in the blood pool is signiﬁcantly
deranged in amyloid patients, but it was not taken
into account when comparing patients with AL
amyloidosis and patients with ATTR amyloidosis.
As an example, blood pool early darkening after
contrast administration is a typical feature of AL
amyloidosis due to the rapid contrast washout fromthe blood pool into the systemic interstitial space,
which is extremely enlarged by light chain deposition
(3–5); similar indexes of contrast kinetics might have
been investigated in the study.
Overall, CMR showed high diagnostic accuracy
in detecting cardiac amyloidosis. In particular,
contrast enhancement was present in all patients
except 1 patient with AL amyloidosis with positive
extracardiac biopsy and echocardiographic criteria
for cardiac involvement but no proven cardiac
involvement by endomyocardial biopsy. Similarly,
12 patients with a negative ﬁnal diagnosis at CMR
showed positive contrast enhancement, making
contrast enhancement 100% sensitive to detect car-
diac amyloidosis. On the other hand, there were only
6 patients with false-positive results, who presented
cardiac hypertrophy with gadolinium contrast
enhancement at CMR but interstitial collagen accu-
mulation rather than amyloid deposition at endo-
myocardial biopsy (3 hypertensive, 2 hypertrophic, 1
alcoholic cardiomyopathy); a subtly different gado-
linium kinetics (an earlier enhancement in amyloid-
osis vs. a later enhancement in ﬁbrosis) could have
been hypothetically disclosed by a careful analysis of
gadolinium enhancement over time.
We agree with the authors that the increased
availability of CMR has led to increased detection of
cardiac amyloidosis, superior tissue characterization,
and possible differentiation between interstitial dis-
eases (inﬂammation, ﬁbrosis, amyloid). The different
biochemical properties of amyloid subtypes likely
explain not only the variable imaging features but
also the distinct prognosis. Further studies are
needed to expand the results of the present study,
possibly investigating the complexity of cardiac in-
terstitial remodeling with novel T1 mapping tech-
niques and correlating CMR ﬁndings with established
biohumoral (natriuretic peptides, troponins), func-
tional (peak oxygen consumption), electrocardio-
graphic, and echocardiographic parameters.Andrea Barison, MD, PhD*
Pier Giorgio Masci, MD, PhD
Giovanni Donato Aquaro, MD
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Cardiac AmyloidosisWe thank Barison et al. for their interest in our
paper (1). Cardiac amyloidosis is gaining signiﬁcant
exposure in the cardiac magnetic resonance (CMR)
community because of the characteristic and near
pathognomonic ﬁndings with the technique. We
reported the ﬁrst study that speciﬁcally aimed to
differentiate between the light chain (AL) and trans-
thyretin (ATTR) subtypes of amyloidosis through re-
trospective analysis of studies performed in multiple
hospitals referring toa specialist amyloidosis center (1).
We did not include right ventricular volumes,
mass, and ejection fraction in the analyses because
not all studies included sufﬁcient images to perform
accurate analysis. Right ventricular morphology data
(particularly right ventricular mass) are less repro-
ducible, even in single center studies (2), and in this
series axial data sets had rarely been routinely
obtained (3). The Query Amyloid Late Enhancement
score, a novel late gadolinium enhancement anal-
ysis, was designed to be a simple add-on to standard
reporting. Various versions of the Query Amyloid
Late Enhancement score were devised, incor-
porating other CMR variables, but we and the re-
viewers decided to report the score independently,
without including potentially confounding factors,
because it was a standalone predictor of amyloidtype. The thinness of the atrial chambers precludes
their use as a reliable measurement when assessing
late gadolinium enhancement. Altered gadolinium
kinetics, already widely reported in cardiac amyloi-
dosis, appear very similar between amyloid types (4),
but further quantitative assessment in this multiple
center, multiple protocol study was not feasible.
Overall, the comments highlight the limitations of
any retrospective study, but we would like to reinforce
the view that our ﬁndings were actually strengthened
by the study design. The data were derived from
nonstandardized protocols performed on various
scanners; however, despite this, an obvious difference
between the amyloid subtypes was shown. Our results
are therefore relevant to nonspecialist CMR centers,
which often raise the possibility of amyloidosis for the
clinicians who refer patients for CMR. Prospective
studies with specialist amyloid protocols may seem
ideal; however, in the real world, our results are
applicable to all CMR operators.Jason N. Dungu, MBBS, BSc*
Lisa J. Anderson, MD
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